NPC1L1 and prostate carcinoma: Moreover, the lack of evidence for an association between PCSK9 inhibition and the risk of advanced prostate cancer, as well as comparatively wider confidence intervals for associations between HMGCR, NPC1L1, and prostate cancer (compared to genetically proxied PCSK9 inhibition) could potentially be due to lack of power.